The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis

To estimate the incubation-period distribution (time from seroconversion to AIDS) accounting for death before an AIDS diagnosis (DBAD) in a cohort of injecting drug users (IDU) in Amsterdam, The Netherlands and to compare these estimates with those previously obtained from a contemporaneous study of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS (London) 1998-08, Vol.12 (12), p.1537-1544
Hauptverfasser: HENDRIKS, J. C. M, SATTEN, G. A, VAN AMEIJDEN, E. J. C, VAN DRUTEN, H. A. M, COUTINHO, R. A, VAN GRIENSVEN, G. J. P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1544
container_issue 12
container_start_page 1537
container_title AIDS (London)
container_volume 12
creator HENDRIKS, J. C. M
SATTEN, G. A
VAN AMEIJDEN, E. J. C
VAN DRUTEN, H. A. M
COUTINHO, R. A
VAN GRIENSVEN, G. J. P
description To estimate the incubation-period distribution (time from seroconversion to AIDS) accounting for death before an AIDS diagnosis (DBAD) in a cohort of injecting drug users (IDU) in Amsterdam, The Netherlands and to compare these estimates with those previously obtained from a contemporaneous study of homosexual and bisexual men in Amsterdam carried out using the same facilities. Participants in a cohort study begun in Amsterdam at the end of 1985 have scheduled follow-up visits every 4 months. All participants of Dutch nationality and who had two or more follow-up visits before January 1996 from which CD4 measurements were available were included in this study. Data concerning AIDS diagnosis and death were verified through review of national and municipal registries. Because time of seroconversion was unknown for study participants and because IDU are at substantial risk for DBAD, we used a Markov model with CD4-based stages that allows for DBAD. The parameters in this model were estimated using the method of maximum likelihood and confidence intervals were calculated using bootstrap methods. A total of 173 IDU (134 seroprevalent, 39 seroincident) made 1829 visits. Nearly 10% of the visits were non-consecutive. Forty-five IDU developed AIDS and 25 died without an AIDS diagnosis. We estimated that 24% [95% confidence interval (CI), 17-25%] of IDU die before an AIDS diagnosis. As a result, the median time from seroconversion to AIDS (10.5 years; 95% CI, 9.1-10.7 years) is considerably longer than the median time from seroconversion to death (8.3 years; 95% CI, 7.9-8.5 years). Conditional on survival to an AIDS diagnosis, the median time to AIDS is 8.2 years (95% CI, 7.7-8.7 years). The median survival time after a diagnosis of AIDS is estimated to be 1.0 years. The high occurrence of DBAD in IDU has a considerable influence on estimates of the incubation-period distribution. Progression from seroconversion to death was faster in the IDU cohort than in a cohort of homosexual men in Amsterdam (median, 8.3 years and 9.6 years, respectively). However, progression to AIDS conditional on survival to an AIDS diagnosis seems to be similar in both the IDU cohort and in the cohort of homosexual men (median, 8.2 years and 8.3 years, respectively).
doi_str_mv 10.1097/00002030-199812000-00017
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16504159</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16504159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-45352c5901229a3cf4509d1afc8afe3db61b538c1390c6028c89535c3a7a80443</originalsourceid><addsrcrecordid>eNo9UV1vFCEUJUZT1-pPMOHB-OQoH8MAj039aJMmPlifJ3cvzC7NDKzANPE3-KfF7roEciHnnHuAQwjl7CNnVn9ibQgmWcetNVy0U9cW18_Ihvdadkpp_pxsmBhsZ6VmL8mrUh4aRTFjLsiF1UIrPWzIn_u9pyHiuoUaUqQHn0NytCZ6dfv5R0PafPBYQ9xRl9cdXYvPhfpSwwLVOzrltNBD9o8w-1gppn3KlTqo8IECYlrjk3ZKmToPdd-4oe2bAcSjhwuwi6mE8pq8mGAu_s2pXpKfX7_cX990d9-_3V5f3XXYC1a7XkklUFnGhbAgceoVs47DhAYmL9124FslDXJpGQ5MGDS2SVCCBsP6Xl6S98e-h5x-re0p4xIK-nmG6NNaRj4o1nNlG9EciZhTKdlPY7v8Avn3yNn4L4fxfw7jOYfxKYcmfXvyWLeLd2fh6eMb_u6EQ0GYpwwRQznThBxaRy7_AuCBkDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16504159</pqid></control><display><type>article</type><title>The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis</title><source>MEDLINE</source><source>EZB Free E-Journals</source><source>Journals@Ovid Complete</source><creator>HENDRIKS, J. C. M ; SATTEN, G. A ; VAN AMEIJDEN, E. J. C ; VAN DRUTEN, H. A. M ; COUTINHO, R. A ; VAN GRIENSVEN, G. J. P</creator><creatorcontrib>HENDRIKS, J. C. M ; SATTEN, G. A ; VAN AMEIJDEN, E. J. C ; VAN DRUTEN, H. A. M ; COUTINHO, R. A ; VAN GRIENSVEN, G. J. P</creatorcontrib><description>To estimate the incubation-period distribution (time from seroconversion to AIDS) accounting for death before an AIDS diagnosis (DBAD) in a cohort of injecting drug users (IDU) in Amsterdam, The Netherlands and to compare these estimates with those previously obtained from a contemporaneous study of homosexual and bisexual men in Amsterdam carried out using the same facilities. Participants in a cohort study begun in Amsterdam at the end of 1985 have scheduled follow-up visits every 4 months. All participants of Dutch nationality and who had two or more follow-up visits before January 1996 from which CD4 measurements were available were included in this study. Data concerning AIDS diagnosis and death were verified through review of national and municipal registries. Because time of seroconversion was unknown for study participants and because IDU are at substantial risk for DBAD, we used a Markov model with CD4-based stages that allows for DBAD. The parameters in this model were estimated using the method of maximum likelihood and confidence intervals were calculated using bootstrap methods. A total of 173 IDU (134 seroprevalent, 39 seroincident) made 1829 visits. Nearly 10% of the visits were non-consecutive. Forty-five IDU developed AIDS and 25 died without an AIDS diagnosis. We estimated that 24% [95% confidence interval (CI), 17-25%] of IDU die before an AIDS diagnosis. As a result, the median time from seroconversion to AIDS (10.5 years; 95% CI, 9.1-10.7 years) is considerably longer than the median time from seroconversion to death (8.3 years; 95% CI, 7.9-8.5 years). Conditional on survival to an AIDS diagnosis, the median time to AIDS is 8.2 years (95% CI, 7.7-8.7 years). The median survival time after a diagnosis of AIDS is estimated to be 1.0 years. The high occurrence of DBAD in IDU has a considerable influence on estimates of the incubation-period distribution. Progression from seroconversion to death was faster in the IDU cohort than in a cohort of homosexual men in Amsterdam (median, 8.3 years and 9.6 years, respectively). However, progression to AIDS conditional on survival to an AIDS diagnosis seems to be similar in both the IDU cohort and in the cohort of homosexual men (median, 8.2 years and 8.3 years, respectively).</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/00002030-199812000-00017</identifier><identifier>PMID: 9727576</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Acquired Immunodeficiency Syndrome - diagnosis ; Acquired Immunodeficiency Syndrome - mortality ; Acquired Immunodeficiency Syndrome - physiopathology ; Adult ; Biological and medical sciences ; Cause of Death ; CD4 Lymphocyte Count ; Cohort Studies ; Disease Progression ; Female ; HIV Seropositivity - epidemiology ; Homosexuality, Male ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Markov Chains ; Medical sciences ; Middle Aged ; Registries ; Substance Abuse, Intravenous - complications ; Time Factors ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>AIDS (London), 1998-08, Vol.12 (12), p.1537-1544</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-45352c5901229a3cf4509d1afc8afe3db61b538c1390c6028c89535c3a7a80443</citedby><cites>FETCH-LOGICAL-c420t-45352c5901229a3cf4509d1afc8afe3db61b538c1390c6028c89535c3a7a80443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2361991$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9727576$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HENDRIKS, J. C. M</creatorcontrib><creatorcontrib>SATTEN, G. A</creatorcontrib><creatorcontrib>VAN AMEIJDEN, E. J. C</creatorcontrib><creatorcontrib>VAN DRUTEN, H. A. M</creatorcontrib><creatorcontrib>COUTINHO, R. A</creatorcontrib><creatorcontrib>VAN GRIENSVEN, G. J. P</creatorcontrib><title>The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>To estimate the incubation-period distribution (time from seroconversion to AIDS) accounting for death before an AIDS diagnosis (DBAD) in a cohort of injecting drug users (IDU) in Amsterdam, The Netherlands and to compare these estimates with those previously obtained from a contemporaneous study of homosexual and bisexual men in Amsterdam carried out using the same facilities. Participants in a cohort study begun in Amsterdam at the end of 1985 have scheduled follow-up visits every 4 months. All participants of Dutch nationality and who had two or more follow-up visits before January 1996 from which CD4 measurements were available were included in this study. Data concerning AIDS diagnosis and death were verified through review of national and municipal registries. Because time of seroconversion was unknown for study participants and because IDU are at substantial risk for DBAD, we used a Markov model with CD4-based stages that allows for DBAD. The parameters in this model were estimated using the method of maximum likelihood and confidence intervals were calculated using bootstrap methods. A total of 173 IDU (134 seroprevalent, 39 seroincident) made 1829 visits. Nearly 10% of the visits were non-consecutive. Forty-five IDU developed AIDS and 25 died without an AIDS diagnosis. We estimated that 24% [95% confidence interval (CI), 17-25%] of IDU die before an AIDS diagnosis. As a result, the median time from seroconversion to AIDS (10.5 years; 95% CI, 9.1-10.7 years) is considerably longer than the median time from seroconversion to death (8.3 years; 95% CI, 7.9-8.5 years). Conditional on survival to an AIDS diagnosis, the median time to AIDS is 8.2 years (95% CI, 7.7-8.7 years). The median survival time after a diagnosis of AIDS is estimated to be 1.0 years. The high occurrence of DBAD in IDU has a considerable influence on estimates of the incubation-period distribution. Progression from seroconversion to death was faster in the IDU cohort than in a cohort of homosexual men in Amsterdam (median, 8.3 years and 9.6 years, respectively). However, progression to AIDS conditional on survival to an AIDS diagnosis seems to be similar in both the IDU cohort and in the cohort of homosexual men (median, 8.2 years and 8.3 years, respectively).</description><subject>Acquired Immunodeficiency Syndrome - diagnosis</subject><subject>Acquired Immunodeficiency Syndrome - mortality</subject><subject>Acquired Immunodeficiency Syndrome - physiopathology</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cause of Death</subject><subject>CD4 Lymphocyte Count</subject><subject>Cohort Studies</subject><subject>Disease Progression</subject><subject>Female</subject><subject>HIV Seropositivity - epidemiology</subject><subject>Homosexuality, Male</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Markov Chains</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Registries</subject><subject>Substance Abuse, Intravenous - complications</subject><subject>Time Factors</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UV1vFCEUJUZT1-pPMOHB-OQoH8MAj039aJMmPlifJ3cvzC7NDKzANPE3-KfF7roEciHnnHuAQwjl7CNnVn9ibQgmWcetNVy0U9cW18_Ihvdadkpp_pxsmBhsZ6VmL8mrUh4aRTFjLsiF1UIrPWzIn_u9pyHiuoUaUqQHn0NytCZ6dfv5R0PafPBYQ9xRl9cdXYvPhfpSwwLVOzrltNBD9o8w-1gppn3KlTqo8IECYlrjk3ZKmToPdd-4oe2bAcSjhwuwi6mE8pq8mGAu_s2pXpKfX7_cX990d9-_3V5f3XXYC1a7XkklUFnGhbAgceoVs47DhAYmL9124FslDXJpGQ5MGDS2SVCCBsP6Xl6S98e-h5x-re0p4xIK-nmG6NNaRj4o1nNlG9EciZhTKdlPY7v8Avn3yNn4L4fxfw7jOYfxKYcmfXvyWLeLd2fh6eMb_u6EQ0GYpwwRQznThBxaRy7_AuCBkDg</recordid><startdate>19980820</startdate><enddate>19980820</enddate><creator>HENDRIKS, J. C. M</creator><creator>SATTEN, G. A</creator><creator>VAN AMEIJDEN, E. J. C</creator><creator>VAN DRUTEN, H. A. M</creator><creator>COUTINHO, R. A</creator><creator>VAN GRIENSVEN, G. J. P</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19980820</creationdate><title>The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis</title><author>HENDRIKS, J. C. M ; SATTEN, G. A ; VAN AMEIJDEN, E. J. C ; VAN DRUTEN, H. A. M ; COUTINHO, R. A ; VAN GRIENSVEN, G. J. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-45352c5901229a3cf4509d1afc8afe3db61b538c1390c6028c89535c3a7a80443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Acquired Immunodeficiency Syndrome - diagnosis</topic><topic>Acquired Immunodeficiency Syndrome - mortality</topic><topic>Acquired Immunodeficiency Syndrome - physiopathology</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cause of Death</topic><topic>CD4 Lymphocyte Count</topic><topic>Cohort Studies</topic><topic>Disease Progression</topic><topic>Female</topic><topic>HIV Seropositivity - epidemiology</topic><topic>Homosexuality, Male</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Markov Chains</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Registries</topic><topic>Substance Abuse, Intravenous - complications</topic><topic>Time Factors</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HENDRIKS, J. C. M</creatorcontrib><creatorcontrib>SATTEN, G. A</creatorcontrib><creatorcontrib>VAN AMEIJDEN, E. J. C</creatorcontrib><creatorcontrib>VAN DRUTEN, H. A. M</creatorcontrib><creatorcontrib>COUTINHO, R. A</creatorcontrib><creatorcontrib>VAN GRIENSVEN, G. J. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HENDRIKS, J. C. M</au><au>SATTEN, G. A</au><au>VAN AMEIJDEN, E. J. C</au><au>VAN DRUTEN, H. A. M</au><au>COUTINHO, R. A</au><au>VAN GRIENSVEN, G. J. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>1998-08-20</date><risdate>1998</risdate><volume>12</volume><issue>12</issue><spage>1537</spage><epage>1544</epage><pages>1537-1544</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>To estimate the incubation-period distribution (time from seroconversion to AIDS) accounting for death before an AIDS diagnosis (DBAD) in a cohort of injecting drug users (IDU) in Amsterdam, The Netherlands and to compare these estimates with those previously obtained from a contemporaneous study of homosexual and bisexual men in Amsterdam carried out using the same facilities. Participants in a cohort study begun in Amsterdam at the end of 1985 have scheduled follow-up visits every 4 months. All participants of Dutch nationality and who had two or more follow-up visits before January 1996 from which CD4 measurements were available were included in this study. Data concerning AIDS diagnosis and death were verified through review of national and municipal registries. Because time of seroconversion was unknown for study participants and because IDU are at substantial risk for DBAD, we used a Markov model with CD4-based stages that allows for DBAD. The parameters in this model were estimated using the method of maximum likelihood and confidence intervals were calculated using bootstrap methods. A total of 173 IDU (134 seroprevalent, 39 seroincident) made 1829 visits. Nearly 10% of the visits were non-consecutive. Forty-five IDU developed AIDS and 25 died without an AIDS diagnosis. We estimated that 24% [95% confidence interval (CI), 17-25%] of IDU die before an AIDS diagnosis. As a result, the median time from seroconversion to AIDS (10.5 years; 95% CI, 9.1-10.7 years) is considerably longer than the median time from seroconversion to death (8.3 years; 95% CI, 7.9-8.5 years). Conditional on survival to an AIDS diagnosis, the median time to AIDS is 8.2 years (95% CI, 7.7-8.7 years). The median survival time after a diagnosis of AIDS is estimated to be 1.0 years. The high occurrence of DBAD in IDU has a considerable influence on estimates of the incubation-period distribution. Progression from seroconversion to death was faster in the IDU cohort than in a cohort of homosexual men in Amsterdam (median, 8.3 years and 9.6 years, respectively). However, progression to AIDS conditional on survival to an AIDS diagnosis seems to be similar in both the IDU cohort and in the cohort of homosexual men (median, 8.2 years and 8.3 years, respectively).</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>9727576</pmid><doi>10.1097/00002030-199812000-00017</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-9370
ispartof AIDS (London), 1998-08, Vol.12 (12), p.1537-1544
issn 0269-9370
1473-5571
language eng
recordid cdi_proquest_miscellaneous_16504159
source MEDLINE; EZB Free E-Journals; Journals@Ovid Complete
subjects Acquired Immunodeficiency Syndrome - diagnosis
Acquired Immunodeficiency Syndrome - mortality
Acquired Immunodeficiency Syndrome - physiopathology
Adult
Biological and medical sciences
Cause of Death
CD4 Lymphocyte Count
Cohort Studies
Disease Progression
Female
HIV Seropositivity - epidemiology
Homosexuality, Male
Human viral diseases
Humans
Infectious diseases
Male
Markov Chains
Medical sciences
Middle Aged
Registries
Substance Abuse, Intravenous - complications
Time Factors
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
title The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T15%3A33%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20incubation%20period%20to%20AIDS%20in%20injecting%20drug%20users%20estimated%20from%20prevalent%20cohort%20data,%20accounting%20for%20death%20prior%20to%20an%20AIDS%20diagnosis&rft.jtitle=AIDS%20(London)&rft.au=HENDRIKS,%20J.%20C.%20M&rft.date=1998-08-20&rft.volume=12&rft.issue=12&rft.spage=1537&rft.epage=1544&rft.pages=1537-1544&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/00002030-199812000-00017&rft_dat=%3Cproquest_cross%3E16504159%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16504159&rft_id=info:pmid/9727576&rfr_iscdi=true